Next-generation sequencing (NGS) is changing cancer treatment in India, shifting toward personalized care. The market is projected to reach $1.5 billion by 2030, growing at an annual rate of 27%. While this trend supports expansion for hospitals and diagnostic firms, investors should track challenges like high test costs, drug affordability, and the need for India-specific genetic data.
What Happened
India’s cancer care sector is seeing a significant shift toward precision medicine, driven by Next-Generation Sequencing (NGS). Unlike traditional methods that treat all patients with similar protocols, NGS allows doctors to decode a patient’s genetic data to pinpoint specific mutations. This change is moving cancer care away from one-size-fits-all chemotherapy toward highly targeted treatments, which can often reduce side effects and improve patient recovery rates.
Market Growth and Investment Potential
The precision oncology market in India is expanding rapidly. Industry projections suggest the market could reach $1.5 billion by 2030, with a compound annual growth rate of 27%. The broader precision medicine market is expected to grow even faster, with estimates predicting a fivefold increase to $5.8 billion.
This growth is attracting investment from major hospital chains and diagnostic players. Large hospital networks, such as Apollo Hospitals, are expanding their internal genomics facilities to offer these tests. Furthermore, global biotech firms, including Illumina, are increasing their presence in India to support massive government-backed initiatives like the Genome India project. For healthcare providers, this represents a new, high-value service vertical that could boost revenue as demand for personalized diagnostics rises.
The Data and Access Challenge
Despite the growth, the business of precision medicine faces real-world hurdles. One major challenge is the lack of population-specific data. Genetic patterns in the Indian population often differ from those found in Western cohorts, meaning global genomic databases are not always fully applicable to Indian patients. This requires companies to invest in localized research and data collection to ensure their diagnostic tests and drugs are effective.
Additionally, affordability remains a primary barrier to scale. While basic cancer screenings are more accessible, comprehensive genomic panels can cost up to Rs 4 lakh. Even if a patient can afford the test, the associated targeted drugs are often expensive, creating a bottleneck for widespread adoption. Initiatives like the LuNGS (Lung Cancer Genomic Solutions) Alliance are attempting to bridge this gap by providing free tests for lung cancer patients in tier-2 and tier-3 cities, but long-term commercial sustainability depends on reducing the cost of both diagnostics and the drugs they prescribe.
What Investors Should Track
Investors monitoring this sector should look beyond the market size projections. Key monitorables include the adoption rate of NGS in smaller cities, as profitability at scale depends on volume. It is also important to track how diagnostic and hospital companies partner with pharmaceutical firms to create affordable treatment ecosystems. Finally, watch for advancements in localized research, as companies that can effectively bridge the data gap between Indian patient profiles and global treatment standards may hold a stronger competitive advantage.